Sermorelin Overview
Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) used primarily for diagnostic testing of growth hormone deficiency in children and has limited therapeutic applications in pediatric idiopathic growth hormone deficiency. 1
What is Sermorelin?
Sermorelin represents the shortest synthetic peptide that retains full biological activity of GHRH. It specifically stimulates growth hormone secretion from the anterior pituitary gland through direct receptor activation 1.
Primary Indication
Diagnostic Use
- Intravenous sermorelin at 1 mcg/kg bodyweight serves as a rapid and relatively specific provocative test for diagnosing growth hormone deficiency in children 1
- Produces fewer false-positive growth hormone responses compared to other provocative tests
- Critical caveat: Normal growth hormone response to sermorelin cannot exclude hypothalamic-origin growth hormone deficiency—subnormal responses to other provocative tests are needed to confirm diagnosis in these cases 1
Therapeutic Use (Limited)
- Treatment of some prepubertal children with idiopathic growth hormone deficiency
- Not a first-line therapy—the evidence base is substantially weaker than for recombinant growth hormone (somatropin)
Dosing Regimen
Diagnostic Testing
- Single intravenous dose: 1 mcg/kg bodyweight 1
Therapeutic Use (when considered)
- Subcutaneous: 30 mcg/kg bodyweight once daily at bedtime 1
- Limited data show sustained increases in height velocity over 12 months, with some data suggesting maintenance through 36 months
- Important limitation: Direct comparison studies show sermorelin 30 mcg/kg/day (whether as continuous infusion or divided doses) produces smaller increases in height velocity than once-daily somatropin 30 mcg/kg 1
Patient Selection for Therapeutic Use
When sermorelin is considered therapeutically, best responses occur in:
- Slow-growing children
- Shorter stature
- Delayed bone age
- Delayed height age 1
Contraindications
While specific contraindications for sermorelin are not detailed in the provided evidence, standard growth hormone therapy contraindications should apply based on endocrine society guidelines:
- Active malignancy 2
- Patients should be evaluated for structural hypothalamic/pituitary disease before treatment 2
Monitoring Parameters
Based on growth hormone therapy principles 2:
- Clinical assessment at 1-2 month intervals during dose titration
- Semiannual monitoring thereafter including:
- IGF-I levels
- Clinical response parameters
- Adverse effects evaluation
- Height velocity
- Thyroid and adrenal function monitoring (as GH therapy can affect these axes) 2
- Glucose metabolism monitoring in patients with diabetes, as adjustments in antidiabetic medications may be required 2
Adverse Effects
Sermorelin demonstrates excellent tolerability with minimal adverse events 1:
Most Common
- Transient facial flushing (most frequently reported)
- Pain at injection site
General Safety Profile
- Both single intravenous doses and repeated subcutaneous daily doses are well tolerated
- Significantly better safety profile than many other growth hormone secretagogues
Critical Clinical Considerations
Sermorelin is NOT equivalent to recombinant growth hormone therapy—it produces inferior height velocity gains compared to somatropin 1
Diagnostic limitations: Cannot rule out hypothalamic growth hormone deficiency with normal response alone 1
Long-term efficacy unknown: Effects on final adult height remain undetermined 1
Limited evidence base: Therapeutic use is supported by limited data compared to the robust evidence for recombinant growth hormone 2, 1
Not mentioned in current endocrine society guidelines: The 2011 Endocrine Society guidelines for adult growth hormone deficiency do not include sermorelin as a recommended therapeutic agent, focusing instead on recombinant GH therapy 2
Important Pitfall
Do not confuse the FDA drug label information provided for sertraline (an SSRI antidepressant) with sermorelin 3. These are completely different medications—sertraline treats psychiatric conditions while sermorelin is a growth hormone secretagogue.